Affymetrix two weeks ago told analysts that it expects to start recording revenue from its $120 million acquisition of ParAllele Bioscience by the end of the year.
Affy acquired ParAllele in October 2005 for its genotyping technology, which Affy said would "help accelerate the commercialization and development of DNA analysis products."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.